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Abstract
Background: Human papillomavirus (HPV) testing as primary screening for cervical cancer is currently being
implemented in Norway in a randomized controlled fashion, involving three laboratories. As part of the quality
assurance programme of the implementation, an evaluation of the inter-laboratory reproducibility of the HPV test
was initiated, to ensure satisfactory HPV test reliability in all three laboratories.
Methods: The HPV test used is the cobas 4800 HPV Test, detecting 14 high-risk types with individual HPV genotype
results for HPV16 and HPV18. In addition to the three laboratories involved in the implementation, the Norwegian
HPV reference laboratory was included as a fourth comparative laboratory. A stratified sample of 500 cervical liquid
based cytology (LBC) samples was used in the evaluation, with an aim towards a high-risk HPV positivity of ~25%.
Samples were collected at one laboratory, anonymized, aliquoted, and distributed to the other laboratories.
Results: Comparison of the test results of all four laboratories revealed a 95.6% agreement, an 86.3% positive
agreement and a kappa value of 0.94 (95% CI 0.92–0.97). For negative cytology specimens, there was a 95.8%
overall agreement, a 67.4% positive agreement, and a kappa value of 0.88 (95% CI 0.80–0.93). For abnormal
cytology specimens, there was a 95.8% overall agreement, a 95.5% positive agreement, and a kappa value of 0.86
(95% CI 0.71–0.97).
Conclusions: The study showed a high inter-laboratory reproducibility of HPV testing, implying satisfactory user
performance and reliability in the laboratories involved in the implementation project. This is important knowledge
and we recommend similar studies always to be performed prior to the introduction of new screening routines.
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Background
Identification of the association between high-risk hu-
man papillomavirus (HR-HPV) and cervical carcinogen-
esis has led to revolutionary advances in cervical cancer
screening, including sensitive, molecular HPV tests that
improve early detection of cervical precancerous lesions.
In Norway, HPV testing was introduced in triage of
women diagnosed with ASC-US (atypical squamous cells
of undetermined significance) and LSIL (low-grade squa-
mous intraepithelial lesions) in 2005. Based on random-
ized clinical trials of HR-HPV detection conducted in
Europe, as well as recommendations by the European
guidelines for quality assurance in cervical cancer
screening [1–3], HPV testing in primary screening has
been introduced in several European countries during
the last few years. The more sensitive and objective HPV
test is proposed to increase health benefit and reduce
the harms associated with screening. In addition, the
objectivity of the test implies better reproducibility
compared to cytology [4]. Still, primary HPV-based
screening has been and is controversial, related to the
low clinical specificity of HPV DNA tests. HPV DNA
testing will identify several infections never leading to
dysplasia or cancer, especially in younger age-groups. Of
this reason, HPV primary screening is commonly intro-
duced for women above the age of 30. Also, low specifi-
city of HPV DNA testing is partly compensated for by
cytological triage of HPV positive women (http://
www.kreftregisteret.no/hpv-algoritme).
In 2015, gradual implementation of primary HPV screen-
ing in the Norwegian cervical cancer screening programme
was initiated. Women in the age group 34–69 years resi-
dent in four (of a total of 19) counties in Norway, are ran-
domized to HPV testing or cytology according to their
date of birth. The HPV analyses are performed by three la-
boratories located at Stavanger University Hospital, Stavan-
ger, Haukeland University Hospital, Bergen and St. Olavs
Hospital, Trondheim University Hospital, Trondheim.
After competitive bidding, the cobas 4800 HPV Test
(Roche Diagnostics) was selected for the implementation.
In 2014, the cobas HPV Test was U.S. Food and Drug-
approved for use in primary cervical cancer screening for
women 25 year and older.
In addition to good clinical performance, reproducibil-
ity of laboratory results is fundamental for safe screen-
ing. To confirm satisfactory HPV test reproducibility
and user performance within the screening programme,
an evaluation of inter-laboratory reproducibility between
the three service laboratories involved in the implemen-
tation was performed. The Norwegian HPV reference
laboratory (Akershus University Hospital, Lørenskog),
with cobas 4800 HPV Test accreditation since 2011,
contributed as a fourth evaluator. Two of the three ser-
vice laboratories had no previous experience with the
test, and a shared laboratory handbook containing ne-
cessary standard operating procedures (SOPs) for HPV
testing was prepared to ensure standardized methods.
The inter-laboratory evaluation of HPV testing reported
here was considered part of the quality assurance
programme of the implementation of HPV primary
screening in Norway, aiming to confirm satisfactory user
performance and reliability in each of the three
laboratories.
Methods
Clinical material and study design
Residual material of cervical liquid based cytology (LBC)
samples (in PreservCyt medium, Hologic, Bedford, MA,
USA) taken as part of the cervical cancer screening
programme in Norway, was used. The samples were col-
lected at Stavanger University Hospital, Department of
Pathology, in the time period December 16th 2014 to
May 21st 2015. All ages were included (comprising ages
16–81 years).
Two-sided Z test (kappa statistic) for agreement be-
tween two rates was used for sample size determination
[5]. Power calculation showed that a sample size of 480
subjects achieved 86% power to detect a true Kappa
value of 0.80 in a test of H0: Kappa = 0.69 vs. H1: Kappa
<> 0.69. The power calculation was based on a signifi-
cance level of 0.05. A total of 500 samples were collected
with a composition aiming to provide an approximate
prevalence of high-risk HPV of 25%. In order to reach
that goal, 100 samples were selected based on the cyto-
logical results, either high-risk HPV DNA positive ASC-
US or LSIL samples; or HSIL (high-grade squamous
intraepithelial lesion) or ASC-H (atypical squamous
cells, cannot rule out HSIL), assumed to be HPV posi-
tive. In addition, 400 consecutive samples without regard
to their cytological results were included.
For ethical reasons, all samples were anonymized be-
fore HPV analysis. Cytological diagnoses were recorded
prior to anonymization, important for the final evalu-
ation of the results. For HSIL and ASC-H samples, a
high concordance is essential. For NILM (negative for
intra-epithelial lesions or malignancy) samples, with a
generally lower viral load expected, a certain degree of
discordance is expected due to the stochasticity of the
PCR process. Due to anonymization of the samples, re-
view of cytological diagnoses and/or comparison to
histological results was not feasible.
One sample was excluded from the analyses due to
empty sample tube upon arrival at one laboratory.
Hence, the presented data are based on results from 499
samples.
Considering all 499 samples, 24% presented samples
with cellular changes (ASC-US 7%, LSIL 7%, ASC-H 2%
and HSIL 8%), while 5% was unsatisfactory for
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cytological evaluation. The sample distribution accord-
ing to cytological result is given in Table 1.
HPV determination
The cobas 4800 HPV Test is a fully automated, qualita-
tive multiplex assay, including full sample preparation
(cobas x 480) and HPV detection (cobas z 480 Analyser)
based on real-time polymerase chain reaction (PCR)
technology. The method detects 14 high-risk types, in-
cluding individual HPV genotype results for HPV16 and
HPV18. The other 12 types are reported concurrently by
a pooled result (HR-HPV). Beta-globin is used as an in-
ternal quality control for each sample. The system is
provided with an advanced result algorithm for the cal-
culation of distinct HPV positive, HPV negative or in-
valid (negative beta-globin) results and the ability to
review reaction curves manually is not routinely avail-
able for users. In addition, of various indicated reasons,
the sample may come up as “failed”, with the most com-
mon explanations being clots or insufficient sample
volume.
Results are reported through four channels specific for
HPV16, HPV18, HR-HPV, or beta-globin, respectively.
Each channel has a distinct cut-off value, based on cycle
threshold (Ct) values to distinguish a clinically positive
from a negative sample. The cut-off values are 40.5,
40.0, 40.0 and 40.0 for the four channels HPV16,
HPV18, HR-HPV and beta-globlin, respectively [6]. Sets
of positive controls (one for each channel; HPV16,
HPV18 and HPV39) and negative controls are included
for each set-up. The 960 sample kit was used by all
laboratories.
Preparation and distribution of clinical material
Cytology was interpreted according to the Bethesda sys-
tem as unsatisfactory, NILM, ASC-US, LSIL, ASC-H
and HSIL. After registration of cytological diagnosis, the
samples were anonymized and given a study identifica-
tion number. The samples were stored within the vali-
dated storage parameters ascribed by the manufacturer,
which says a maximum of 6 months at 2–30 °C. Each
LBC sample was vigorously mixed by using a vortex ma-
chine and aliquoted to four Sarstedt tubes (1.25 ml to
each tube allowing two runs with the cobas HPV Test).
The first set of aliquots was analysed by lab A, the
second by lab B, the third by lab C and the fourth by lab
D (The Norwegian HPV reference laboratory).
Performance at the individual laboratory
Each laboratory (A, B, C and D) tested one set of ali-
quots blinded for all information except for the study
identification number. The samples were run within the
same defined period of two weeks. Samples were
scanned directly onto the instrument and a work-list
(“work order”) was created. The analysis was performed
according to the shared SOPs (www.kreftregisteret.no/
laboratoriemappe). Samples obtaining “failed” results in
the first analysis were rerun once. If persistent, the sam-
ple was reported as failed, and a flag explaining the rea-
son for not being analyzed was attached. Remaining
sample material after analysis was discarded. Results
(raw data) of the testing from each lab were exported to
Excel (Microsoft Office) and sent to the Cancer Registry
of Norway for analysis and interpretation.
Statistical analyses
The inter-laboratory reproducibility was assessed by
comparison of the test results using percentage agree-
ment, positive percentage agreement and Fleiss’ kappa
statistics. Differences in test results were compared pair-
wise between the laboratories using McNemar test. Stata
version 14.1 (Stata Corporation, College Station) was
used for the analyses.
Results
HPV test results showed a mean HPV positivity rate of
28.9% for the four laboratories, varying from 28.3 to
29.3% (Table 2). Table 2 shows the frequency of HPV
negative, HPV positive and failed samples for the labora-
tories, stratified on the cytological categories NILM,
ASC-US, LSIL, ASC-H/HSIL and unsatisfactory.
Agreement between the laboratories was calculated by
overall percentage agreement, positive percentage agree-
ment and Fleiss’ kappa. Comparison of the results from
all four laboratories revealed 95.6% overall agreement,
86.3% positive agreement and a kappa value of 0.94 (95%
CI 0.92–0.97) (Table 2). A pairwise comparison (not ad-
justed for multiple comparisons) did not reveal a signifi-
cant difference between the results from the four
laboratories (p > 0.05). Reproducibility between the la-
boratories was not dependent on cytological
Table 1 Distribution of cytological diagnoses among the 499 samples
NILM N = 355 ASC-US N = 36 LSIL N = 33 ASC-H N = 11 HSIL N = 38 Unsatisfactory N = 27
100 selected samples 0 28a 28a 11 33 0
399 consecutive samples 354 8 5 0 5 27
aHPV positive samples
NILM negative for intraepithelial lesion or malignancy, ASC-US atypical squamous cells of undetermined significance, LSIL low-grade squamous intraepithelial
lesion, ASC-H atypical squamous cells, cannot exclude a high-grade lesion, HSIL high-grade squamous intraepithelial lesion
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Table 2 Frequencies of HPV negative, HPV positive and failed samples considering all 499 samples, stratified on cytological categories
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9 (7.6) 0 (0.0)
% Overall
Agreement
95.6 (93.8–97.2) 95.8 (93.5–97.7) 94.4 (86.1–100.0) 90.9 (78.8–100.0) 100.0 (100.0–100.0) 92.6 (81.5–100.0) 95.8 (92.4–99.2)
% Positive
Agreement
90.8 (85.9–94.9) 79.4 (65.1–91.5) 93.9 (84.8–100.0) 90.9 (78.8–100.0) 100.0 (100.0–100.0) 66.7 (0.0–100.0) 95.5 (91.4–99.1)
Kappa 0.94 (0.92–0.97) 0.88 (0.80–0.93) 0.86 (0.52–1.00) n/a 1.0 0.78 (−0.03–1.00) 0.86 (0.71–0.97)
Agreement statistics with 95% confidence intervals between the laboratories are shown
NILM negative for intraepithelial lesion or malignancy, ASC-US atypical squamous cells of undetermined significance, LSIL low-grade squamous intraepithelial lesion, ASC-H atypical squamous cells, cannot exclude a














interpretation. Notably, a 100% agreement was obtained
for the samples with the most severe cytological inter-
pretation (ASC-H and HSIL) (Table 2). The lowest inter-
laboratory agreement was observed among results from
women with unsatisfactory cytology (n = 27) with the
overall percent agreement of 92.6 and a kappa value of
0.78.
Of the 499 samples, 22 samples showed discordant re-
sults (Table 3). For 19 samples, one of the four labora-
tories showed discordancy compared to the three other
laboratories. For two samples, two and two laboratories
had the same results. Only one sample showed three dif-
ferent results (HPV positive, HPV negative and failed).
Two categories of discordant results were observed; 1)
Discordancy in terms of a failed sample for at least one
laboratory (n = 12), and 2) Discordancy in terms of HPV
positive vs HPV negative results (n = 10). Comparison of
the test results from all four laboratories, excluding the
failed samples, showed 98.2% overall agreement, 93.9%
positive agreement and a kappa value of 0.98 (95% CI
0.96–0.99). The four involved laboratories reported in
total 15 failed samples. In a clinical setting, these women
would be recalled to take a new cell sample from the
cervix. Almost all of these samples (14/15) came up with
the flag X3 “Clot was detected; Sample was not
processed”.
For the 10 true discordant samples, different follow-up
procedures would be recommended; seven of the samples
had NILM cytology, two ASC-US, three LSIL and one un-
satisfactory, emphasizing that none had severe cytological
abnormalities (ASC-H or HSIL). The Ct-values of the
discordant samples (Additional file 1: Table S1) were gen-
erally above 38.4 (with two exceptions), and hence close
to the clinical Ct cut-off values. The Ct-values of beta-
globin were for all samples between 25.5 and 28, indicat-
ing sufficient quality of the input DNA.
The cobas HPV Test detects HPV16, HPV18 and 12
additional high-risk types in a pooled analysis. In total,
nine samples showed discordant genotype results
(Additional file 2: Table S2). No samples showed complete
discordance, i.e., there was always partial concordance be-
tween the genotypes. Concordance after including geno-
type information, showed 93.8% overall agreement, 78.7%
positive agreement and a kappa value of 0.93 (95% CI
0.91–0.96) (Table 3). Calculation was also performed
stratifying multiple infections according to oncogenic po-
tential of the HPV types present; HPV16>HPV18>HR-
HPV. The results showed 94.4% overall agreement, 82.5%
positive agreement and a kappa value of 0.94 (95% CI
0.91–0.96) (Table 4).
Discussion
Safe implementation of primary HPV testing in cervical
screening programmes is dependent on reliable test re-
sults to maximize the benefits of HPV testing. Currently,
implementation of primary HPV screening is on-going
in Norway, involving women resident in four counties
(and three laboratories). The screening interval for
women with a negative HPV test is 5 years, compared to
3 years with cytology, and endeavors to minimize false
negative results is particularly important. An evaluation
of the inter-laboratory reproducibility of the HPV testing
was initiated as part of the quality assurance
programme. In addition to the three laboratories in-
volved in the implementation, the Norwegian HPV refer-
ence laboratory contributed as a fourth comparing
laboratory. For yearly quality control, the laboratories
are attending the Quality Control for Molecular Diag-
nostics (QCMD) HPV DNA external quality assessment
(EQA) programme.
In general, the HPV testing showed high reproducibil-
ity between the four sites. Both overall, and after stratifi-
cation according to cytological diagnoses and HPV
Table 3 Samples with discordant HPV test results (HPV positive,
HPV negative, failed) between the four laboratories
Cytological finding Lab A Lab B Lab C Lab D
Unsatisfactory failed negative negative negative *
NILM failed negative negative negative *
NILM failed negative failed negative *
NILM negative failed negative negative *
NILM negative failed negative negative *
NILM negative failed negative negative *
NILM negative failed negative negative *
NILM negative failed negative negative *
ASCUS positive positive failed positive *
LSIL positive failed positive positive *
LSIL positive failed positive positive *
LSIL positive positive failed positive *
Unsatisfactory negative positive negative negative **
NILM failed failed negative positive **
NILM positive negative negative negative **
NILM positive positive negative negative **
NILM positive positive positive negative **
NILM negative positive negative negative **
NILM negative positive negative positive **
NILM negative negative negative positive **
NILM negative negative negative positive **
ASCUS negative positive negative negative **
*Samples for which at least one laboratory reported a failed result, and the
women would be recalled to take a new call sample from the cervix
** True discordant samples; would lead to different clinical
follow-up procedures
NILM negative for intraepithelial lesion or malignancy, ASC-US atypical
squamous cells of undetermined significance, LSIL low-grade squamous
intraepithelial lesion
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genotypes, high agreement between the laboratories was
observed, with kappa values above 0.85. The overall
agreement including all samples was 95.6% (95% CI
93.8–97.4%) and the kappa value was 0.95. These re-
sults are well above the recommended lower confi-
dence bound of 87% overall agreement and kappa
value of at least 0.5, suggested by “Guidelines for
HPV test DNA requirement for primary cervical can-
cer screening” authored by Meijer et al. [7].
Detection of HPV is dependent on the number of viral
DNA copies present in the sample. A negative test result
does not guarantee absence of HPV DNA in the sample,
just that the level is below a defined threshold value
based on the clinical characteristics of the test [8]. In
this evaluation, ten samples showed positive vs negative
discordant results, which according to the current
screening algorithm would result in different follow-up
of the women (http://www.kreftregisteret.no/hpv-algor-
itme). For the discordant results, samples with HPV
positive outcomes had high Ct-values (>38.4) with two
exceptions, implying low levels of viral DNA. The dis-
crepancy in test results (HPV negative vs HPV positive)
may be associated with the inherent stochasticity of the
PCR process, i.e., whether the Ct-value will be below or
above the clinical Ct-threshold value for samples with
low viral load, may be related to coincidence. Accord-
ingly, discordant results may also be explained by intra-
laboratory variability.
All samples with a severe cytological diagnosis (ASC-H
or HSIL) had concordant results. This is regarded as a sig-
nificant finding due to the importance in identifying these
women when HPV testing is introduced as a primary
screening test. High-grade lesions generally have higher
viral loads, possibly also explaining the higher concord-
ance rate among these samples. It is noteworthy however,
that four HSIL samples had an HPV negative test result in
all four laboratories. Based on the close relation between
HSIL and HPV infection, false positive cytology results or
false negative HPV results are likely explanations. HPV
testing, although sensitive, may not capture all cases of
disease and hence, these may be true false negative cases.
Due to the anonymisation of samples, recalling of the cy-
tology results and/or comparison with histological data
was, however, not feasible. In the end, given the aim of
this study, the concordance in test results between the la-
boratories was considered a central finding.
According to the algorithm for primary HPV screening
in Norway, HPV genotypes are not reported and all
HPV-positive women have a cytological reflex evalu-
ation. Still, categorizing the genotypes based on the
cobas HPV Test results, may be of interest as it has been
suggested that HPV16 and/or HPV18 positive women
should have a more aggressive follow-up regime com-
pared to women positive for the HR-HPV category [9].
In the present data, discordant results related to geno-
types were observed for nine samples. Discordance in
terms of HPV16/18 versus HR-HPV, is seen for four
samples. Discrepancy in genotype results may be related
to the multiplex PCR process where targets in the reac-
tion compete with each other for resources.
The cobas 4800 instrument automatically “approves”
the results based on algorithmic criteria in the software.
Accordingly, samples may fail to provide a result. Failed
samples are often explained by insufficient material, too
much material or cellular aggregates, or may be a result
of insufficient mixing of the samples before loading on
the instrument. Failed samples were rerun, and upon a
second fail reported as failed in the study report. This is
a common procedure also in routine screening, where
the women are recalled for a new sample after two failed
analyses. For 11 of the 13 samples reported as “failed”
(Table 3), the failure was only reported from one labora-
tory, suggesting the failure being related to technical is-
sues in the laboratory rather than to the quality of the
sample. Samples should before loading always be visually
inspected, evaluating the need for additional mixing or
even removal of cellular aggregates. For primary screen-
ing, this is however not always feasible due to high
quantity of samples and use of the instrument cobas p
480 for automated sample handling. A suggested pro-
cedure would be to evaluate samples prior to reloading
after a failed result.
Along with the implementation of primary HPV test-
ing, proper directions for quality assessment is para-
mount. In Norway, several initiatives are on-going.
Centralization of HPV testing and cytology reading is in
process to ensure a sound environment with high mo-
lecular biology competence for HPV testing and with
sufficient amount of cytology samples to satisfy “the
European guidelines for quality assurance in cervical
cancer screening” of 15,000 samples per year for each
analyzing laboratory [3]. Laboratories performing HPV
Table 4 Agreement of HPV test results between the four laboratories including HPV genotype information




k value (95% CI) Number of samples
Multiple genotypes taken into consideration 93.8 78.7 0.93 (0.91–0.96) 499
Highest risk genotype taken into consideration 94.4 82.5 0.94 (0.91–0.96) 499
Calculations were performed both with and without taking multiple infections into consideration. For calculation not considering multiple infections, HPV type
category with highest oncogenic potential was the deciding factor; HPV16>HPV18>HR-HPV
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testing should have, and maintain, accreditation to
ISO15189 standard. Among others, this involves that
each laboratory should have SOPs describing all steps
from sample arrival to report. In addition, internal qual-
ity assurance (ICA) should ensure that systematic
method verification is performed and approved upon the
implementation of a new HPV test, documenting for ex-
ample internal reproducibility of the assay. Also, the
introduction of kit independent controls should be con-
sidered, which is important not only as an independent
control for each run, but also for the verification of ana-
lytical stability over time. As a necessary supplement to
ICA, all laboratories should regularly participate to
international EQA programmes in order to evaluate and
document adequate performance, as the QCMD HPV
DNA programme. There is, however, a prominent need
for additional panels specifically designed for HPV-based
screening, evaluating performance based on clinical cut-
off values in the test. Importantly, such a proficiency
screening panel is planned by the WHO HPV LabNet-
programme [10], which would constitute an important
contribution to quality assurance of HPV-based cervical
cancer screening. Awaiting such a panel, Norway will, in
addition to participation in the QCMD programme, con-
tinue with circulation of samples between laboratories
every second year as part of the continuous quality as-
surance of the screening programme. Essentially, we
support the message given by Carozzi and collegues
[11], emphasizing the need for international efforts in
order to establish quality guidelines in line with the
change to HPV-based screening in several countries.
Study constraints
For ethical reasons, all samples were anonymized before
HPV-analysis and consequently, comparison to histo-
logical results was not feasible. This would have been
valuable in order to better explain the HPV negative
HSIL samples observed. In the implementation pilot,
only the cobas HPV Test is used and cell samples are
collected in PreservCyt media. Lacking assessment of re-
producibility between several HPV tests and transport
media entails a limitation to the generality of this evalu-
ation, but fulfil the requirement for the Norwegian
implementation.
Conclusions
Transition from HPV testing as a secondary screening
test to primary HPV testing requires a significant
reorganization of laboratory activities. Laboratory staff
needs good information and training to be able to con-
tribute at a high professional level. The assessment of
the inter-laboratory reproducibility of the HPV testing is
an important contribution to the quality assurance.
Overall, the results in this study show a high inter-
laboratory reproducibility of the HPV testing with the
cobas HPV Test, certifying satisfactory laboratory per-
formance in each of the three laboratories involved in
the implementation of HPV primary screening in
Norway. This is important knowledge and we recom-
mend similar studies always to be performed prior to
the introduction of new screening routines.
Additional files
Additional file 1: Table S1. Ct-values for HPV and beta-globin detection
in samples with discordant results. The Ct-values of the discordant samples
were generally above 38.4 (with two exceptions), and hence close to the
clinical Ct cut-off values. The Ct-values of beta-globin were for all samples
between 25.5 and 28, indicating sufficient quality of the input DNA.
(DOCX 18 kb)
Additional file 2: Table S2. Discordant genotype results among HPV
positive samples. Nine samples showed discordant genotype results. No
samples showed complete discordance, i.e., there was always partial
concordance between the genotypes. (DOCX 15 kb)
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